Anika Therapeutics, Inc.
ANIK· Nasdaq
ANIKAnika Therapeutics, Inc.
Released Nov 8, 2022, after the close
10-Q filed Nov 9, 2022, 40 days after period end · 0001171843-22-007281
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Revenue | $40.26M | $39.54M | $31.69M | $29.70M |
| Net Income | -$4.18M | $558.00K | -$6.41M | $9.20M |
| EPS Diluted |
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
| -$0.29 |
| $0.04 |
| -$0.45 |
| $0.66 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
